Literature DB >> 17192300

The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Mian-er Cong1, Walid Heneine, J Gerardo García-Lerma.   

Abstract

It is generally accepted that the fitness cost of resistance mutations plays a role in the persistence of transmitted drug-resistant human immunodeficiency virus type 1 and that mutations that confer a high fitness cost are less able to persist in the absence of drug pressure. Here, we show that the fitness cost of reverse transcriptase (RT) mutations can vary within a 72-fold range. We also demonstrate that the fitness cost of M184V and K70R can be decreased or enhanced by other resistance mutations such as D67N and K219Q. We conclude that the persistence of transmitted RT mutants might range widely on the basis of fitness and that the modulation of fitness cost by mutational interactions will be a critical determinant of persistence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192300      PMCID: PMC1865994          DOI: 10.1128/JVI.02712-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Long-term persistence of primary genotypic resistance after HIV-1 seroconversion.

Authors:  David Pao; Ushan Andrady; Janette Clarke; Gillian Dean; Susan Drake; Martin Fisher; Tanya Green; Siva Kumar; Maurice Murphy; Alan Tang; Stephen Taylor; David White; Gillian Underhill; Deenan Pillay; Patricia Cane
Journal:  J Acquir Immune Defic Syndr       Date:  2004-12-15       Impact factor: 3.731

2.  Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.

Authors:  S Yerly; A Rakik; S K De Loes; B Hirschel; D Descamps; F Brun-Vézinet; L Perrin
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.

Authors:  P Kosalaraksa; M F Kavlick; V Maroun; R Le; H Mitsuya
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Authors:  Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Bonnie Spira; Vidal Essabag; Brian Conway; Richard Lalonde; Rafick-Pierre Sekaly; Mark A Wainberg
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.

Authors:  A de Ronde; M van Dooren; L van Der Hoek; D Bouwhuis; E de Rooij; B van Gemen; R de Boer; J Goudsmit
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.

Authors:  J G García-Lerma; P J Gerrish; A C Wright; S H Qari; W Heneine
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.

Authors:  Rajesh T Gandhi; Alysse Wurcel; Eric S Rosenberg; Mary N Johnston; Nicholas Hellmann; Michael Bates; Martin S Hirsch; Bruce D Walker
Journal:  Clin Infect Dis       Date:  2003-11-17       Impact factor: 9.079

8.  Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.

Authors:  Constance Delaugerre; Laurence Morand-Joubert; Marie-Laure Chaix; Odile Picard; Anne-Genevieve Marcelin; Veronique Schneider; Anne Krivine; Alexandra Compagnucci; Christine Katlama; Pierre-Marie Girard; Vincent Calvez
Journal:  Antivir Ther       Date:  2004-06

9.  Persistence of primary drug resistance among recently HIV-1 infected adults.

Authors:  Jason D Barbour; Frederick M Hecht; Terri Wrin; Teri J Liegler; Clarissa A Ramstead; Michael P Busch; Mark R Segal; Christos J Petropoulos; Robert M Grant
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

10.  Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.

Authors:  Jennifer A Collins; M Gregory Thompson; Elijah Paintsil; Melisa Ricketts; Joanna Gedzior; Louis Alexander
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  59 in total

1.  Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.

Authors:  Mian-Er Cong; Ae S Youngpairoj; Qi Zheng; Wutyi Aung; James Mitchell; Elizabeth Sweeney; Debra L Hanson; R Michael Hendry; Charles Dobard; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Magnitude and sign epistasis among deleterious mutations in a positive-sense plant RNA virus.

Authors:  J Lalić; S F Elena
Journal:  Heredity (Edinb)       Date:  2012-04-11       Impact factor: 3.821

Review 3.  The high cost of fidelity.

Authors:  Sarah B Lloyd; Stephen J Kent; Wendy R Winnall
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01       Impact factor: 2.205

4.  Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.

Authors:  Maame Efua S Sampah; Lin Shen; Benjamin L Jilek; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

Review 5.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

6.  Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network.

Authors:  Joel O Wertheim; Alexandra M Oster; Jeffrey A Johnson; William M Switzer; Neeraja Saduvala; Angela L Hernandez; H Irene Hall; Walid Heneine
Journal:  Virus Evol       Date:  2017-04-19

7.  Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Hongtao Xu; Daniela Moisi; Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.

Authors:  Charlotte Hedskog; Mattias Mild; Johanna Jernberg; Ellen Sherwood; Göran Bratt; Thomas Leitner; Joakim Lundeberg; Björn Andersson; Jan Albert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

9.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

10.  The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

Authors:  Bruce R Schackman; Callie A Scott; Rochelle P Walensky; Elena Losina; Kenneth A Freedberg; Paul E Sax
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.